Amphastar Pharmaceuticals (NASDAQ:AMPH) Issues Quarterly Earnings Results

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.18), Zacks reports. The firm had revenue of $186.98 million during the quarter, compared to analysts' expectations of $188.78 million. Amphastar Pharmaceuticals had a net margin of 21.80% and a return on equity of 26.44%.

Amphastar Pharmaceuticals Stock Down 3.2 %

NASDAQ:AMPH traded down $0.91 during mid-day trading on Monday, hitting $27.52. The stock had a trading volume of 999,415 shares, compared to its average volume of 580,540. The company has a market capitalization of $1.32 billion, a PE ratio of 9.17, a PEG ratio of 2.19 and a beta of 0.81. The stock has a 50-day simple moving average of $34.74 and a two-hundred day simple moving average of $42.57. Amphastar Pharmaceuticals has a twelve month low of $26.98 and a twelve month high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on AMPH shares. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 target price on the stock. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $50.33.

Remove Ads

Insider Activity at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the sale, the director now directly owns 30,471 shares in the company, valued at $1,333,715.67. This trade represents a 24.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Rong Zhou sold 7,000 shares of the business's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now directly owns 118,469 shares of the company's stock, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by corporate insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.